Sun Pharma Advanced Research Company LimitedXelpros (latanoprost ophthalmic emulsion)

NDA 206185 COMPLETE RESPONSE

Sun Pharma Advanced Research Company Limited c/o Ora, Inc. Attention: Mr. Aron Shapiro Vice President, Ora, Inc. 300 Brickstone Square Andover, MA 01810

Dear Mr. Shapiro:

Please refer to your New Drug Application (NDA) dated January 31, 2014, received January 31, 2014, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, for Xelpros (latanoprost ophthalmic emulsion) 0.005%.

We acknowledge receipt of your amendments dated: November 26, 2014

April 9, 2015

May 12, 2015

The April 9, 2015, submission constituted a complete response to our November 24, 2014, action letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this

action below and, where possible, our recommendations to address these issues.

PRESCRIBING INFORMATION

1. Please submit the labeling attached to this correspondence, which contains minor revisions based on the labeling submitted April 9, 2015. Pleas so re-submit the carton and container labels in the April 9, 2015, submission, as these labels are acceptable.

Reference ID: 3800017

NDA 206185 Page 2

FACILITY INSPECTIONS

2. During a recent inspection of the Sun Pharmaceutical Industries, Ltd, Halol, India manufacturing facility for this application, our field investigators conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

PROPRIETARY NAME

3. Please refer to correspondence dated July 16, 2015, which addresses the proposed proprietary name, Xelpros. This name was found acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to the application deficiencies.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at

21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.

2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:

e Present new safety data from the studies/clinical trials for the proposed indication using the same format as the original NDA submission.

¢ Present tabulations of the new safety data combined with the original NDA data.

e Include tables that compare frequencies of adverse events in the original NDA with the retabulated frequencies described in the bullet above.

e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.

3. Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.

4. Provide case report forms and narrative summaries for each patient who died during a clinical trial or who did not complete a trial because of an adverse event. In addition,

provide narrative summaries for serious adverse events.

5. Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original NDA data.

Reference ID: 3800017

NDA 206185 Page 3

6. Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).

7. Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.

8. Provide English translations of current approved foreign labeling not previously submitted.

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may also request an extension of time in which to resubmit the application. A resubmission must fully address all the deficiencies listed. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

Under 21 CFR 314.102(d), you may request a meeting or telephone conference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the FDA Guidance for Industry, “Formal Meetings Between the FDA and Sponsors or Applicants,” May 2009 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U CM153222.pdf.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call Ms. Diana Willard, Chief, Project Management Staff, at (301)

796-1600. Sincerely, {See appended electronic signature page} Renata Albrecht, M.D. Director Division of Transplant and Ophthalmology Products Office of Antimicrobial products Center for Drug Evaluation and Research ENCLOSURES: Labeling

Reference ID: 3800017

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

RENATA ALBRECHT 07/30/2015

Reference ID: 3800017